-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, the application of immunotherapy, especially the PD-1 monoclonal antibody, has caused a sea-shaking change in the treatment of advanced esophageal cancer.
Six months later, great news came from across the ocean.
However, winning the top spot does not mean being proud.
KEYNOTE-590 China's cohort expansion was withdrawn due to program modification, the specific reason is unknown.
In addition, according to the NextClinTrial database, BeiGene, Cinda Bio, Junshi Bio, Fuhong Henlius, and CStone Pharmaceuticals all have a phase 3 clinical trial layout of PD-1/PD-L1 combined with chemotherapy for the first-line treatment of advanced esophageal cancer.
This team is still in the "honest" immune combination chemotherapy, BMS and Roche directly played a "marriage trick.